Osteoarthritis Treatment — OARSI and NICE 2022 Evidence-Based Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Osteoarthritis (OA) is the most common joint disease worldwide, characterised by progressive loss of articular cartilage, subchondral bone remodelling, osteophyte formation, synovitis, and periarticular soft-tissue changes. It affects an estimated 500 million people globally, with the knee, hip, hand, and spine being the most frequently involved sites. OA is not simply 'wear and tear' — it is a complex biologically active disease driven by mechanical, metabolic, inflammatory, and genetic factors.

The treatment of OA is multimodal, combining non-pharmacological, pharmacological, and — in end-stage disease — surgical interventions. Current guidelines from the Osteoarthritis Research Society International (OARSI 2022), the National Institute for Health and Care Excellence (NICE NG226, 2022), and the European League Against Rheumatism (EULAR) share a consistent framework: non-pharmacological core treatments (exercise and weight management) are mandatory first-line interventions for all patients, with pharmacological and surgical options added sequentially based on individual response and clinical need.

A critical insight from contemporary OA research is that exercise and weight loss are not merely adjuncts — they are the most effective and safest interventions available. Multiple meta-analyses demonstrate that structured exercise reduces OA knee and hip pain by 20–30% and improves function comparably to oral NSAIDs, without the gastrointestinal, cardiovascular, and renal risks. Every 1 kg of body weight lost translates to approximately a 4 kg reduction in knee joint compressive load, meaning a 10 kg weight loss reduces knee load by 40 kg with each step — a profound biomechanical benefit.

This guide aligns with OARSI 2022 and NICE NG226 guidance and provides patients with a detailed, evidence-referenced understanding of the full spectrum of OA management options, from lifestyle modification through to total joint replacement surgery and emerging disease-modifying therapies.

Osteoarthritis can affect virtually any synovial joint. The treatment principles described in this guide apply across the major OA subtypes, with some joint-specific variations in pharmacological and surgical options:

• Knee OA (gonarthrosis): The most common and most extensively researched form. May be medial compartment, lateral compartment, patellofemoral, or tibiofemoral (global). Weight loss, quadriceps strengthening, and knee-specific exercise programmes (e.g., GLA:D — Good Life with osteoArthritis in Denmark) have the strongest evidence base. Surgical options include unicompartmental knee arthroplasty (UKA) for isolated medial or lateral disease, and total knee arthroplasty (TKA) for advanced multicompartmental disease.
• Hip OA (coxarthrosis): Significant disability when severe; hip strengthening, aquatic exercise, and weight management are core non-surgical strategies. Total hip arthroplasty (THA) has excellent outcomes — one of the most cost-effective surgical procedures in medicine — and is indicated when conservative management fails per NICE TA395.
• Hand OA: Affects the distal interphalangeal (DIP) and proximal interphalangeal (PIP) joints, first carpometacarpal (thumb base) joint, and occasionally MCP joints. Topical NSAIDs (NICE first-line), hand exercises, splints, and thumb base steroid injections are the primary non-surgical approaches. Surgical options include trapeziectomy ± ligament reconstruction and tendon interposition (LRTI) for thumb base OA.
• Spinal OA (facet joint OA / spondylosis): Managed with physiotherapy, core strengthening, oral analgesia, and facet joint injections. Surgical decompression or fusion is reserved for cases with significant neurological compromise.
• Shoulder OA (glenohumeral OA): Less common; physiotherapy, activity modification, and intra-articular injection prior to total shoulder arthroplasty consideration.

The diagnosis of OA is primarily clinical in the typical age group (>45 years, activity-related pain, morning stiffness <30 minutes) per NICE. Imaging (X-ray) is not required to initiate treatment but is useful to exclude other diagnoses and to stage disease severity when surgery is being considered.

All patients with symptomatic OA causing pain, stiffness, or functional limitation are candidates for treatment. The challenge in OA management is matching treatment intensity and type to disease severity, functional impact, comorbidities, and patient preference.

Non-pharmacological treatment (exercise and weight loss): Appropriate for all patients with OA regardless of severity, age, or comorbidity — there are no contraindications to appropriately graduated exercise. Patients who are obese (BMI >30) or overweight (BMI 25–30) with lower limb OA should be offered structured weight management support alongside exercise, as the combination delivers additive benefit.

Topical NSAIDs: First-line pharmacological therapy for knee and hand OA per NICE 2022. Appropriate for patients without active skin conditions at the application site. Preferred over oral NSAIDs in elderly patients due to minimal systemic absorption and lower GI/cardiovascular risk.

Oral NSAIDs: Used when topical agents provide insufficient pain relief. Contraindicated in: active peptic ulceration, eGFR <30 mL/min, NSAID allergy, and with caution in established cardiovascular disease. Always co-prescribe a PPI (omeprazole 20 mg daily) for patients over 65, those on corticosteroids or anticoagulants, or with any additional GI risk factor. Diclofenac carries the highest cardiovascular risk among common oral NSAIDs.

Duloxetine: Appropriate add-on or alternative for patients with moderate-severe knee OA and chronic pain in whom NSAIDs are contraindicated, poorly tolerated, or insufficiently effective. Also suitable for patients with comorbid depression or anxiety, in whom a single agent can address both mood and pain. Titrate slowly from 30 mg to avoid nausea.

Intra-articular injections: Appropriate when pain is poorly controlled with topical/oral analgesia; often used as a 'bridging' measure while awaiting physiotherapy to take effect or before considering surgery. No more than three corticosteroid injections per joint per year.

Joint replacement surgery referral criteria (NICE TA304/TA395): Referral for TKA or THA should be considered when OA is confirmed radiographically, conservative management including physiotherapy and analgesia have been optimised and inadequate, and the patient has significant pain and functional limitation that substantially impacts quality of life. There is no specific threshold; the decision is shared between patient and surgeon.

1. Exercise Therapy — The Most Important Intervention

Exercise is the cornerstone of OA management and the intervention with the most consistent evidence base. OARSI 2022 and NICE NG226 classify it as a 'core treatment' — mandatory for all patients. A combination of aerobic exercise (brisk walking, cycling, swimming — 150 minutes moderate intensity per week) and targeted muscle strengthening (quadriceps and hip abductors for knee OA; hip muscles for hip OA) achieves the best outcomes. The GLA:D programme — an 8-week structured group physiotherapy programme for knee and hip OA — demonstrates 30% pain reduction and 32% improved function sustained at 12 months in RCT data. Aquatic exercise (hydrotherapy) is particularly effective in patients with severe joint pain limiting land-based exercise.

2. Weight Management

For patients who are overweight or obese, weight loss of at least 10% body weight is recommended to achieve meaningful OA symptom benefit. The IDEA trial demonstrated that diet plus exercise was superior to either intervention alone in overweight knee OA patients. Behavioural weight management programmes, very low calorie diets, and anti-obesity pharmacotherapy (semaglutide GLP-1 agonist reduces OA symptoms through weight loss and potential anti-inflammatory effects — STEP trials) all represent viable pathways.

3. Topical NSAIDs

Topical diclofenac gel 1% (Voltaren Emulgel) is recommended by NICE 2022 and OARSI 2022 as the first pharmacological step for knee and hand OA. Applied 3–4 times daily, topical NSAIDs deliver local tissue concentrations 4–7 times higher than systemic exposure achieved with equivalent oral dosing, with minimal plasma levels and therefore very low GI, cardiovascular, and renal side-effect risk. Number-needed-to-treat (NNT) for meaningful pain relief: approximately 6–8.

4. Oral NSAIDs

Oral NSAIDs (ibuprofen, naproxen, diclofenac, etoricoxib) are effective for OA pain. Naproxen has the most favourable cardiovascular safety profile. Cox-2 selective inhibitors (etoricoxib, celecoxib) offer equivalent efficacy with lower GI risk but higher cardiovascular risk than naproxen. All oral NSAIDs require PPI co-prescription in high-risk patients.

5. Duloxetine

A network meta-analysis published in NEJM Evidence (2023) identified duloxetine as one of the most efficacious pharmacological agents for knee OA — delivering approximately a 10% greater pain reduction than placebo (small but clinically meaningful). NNT for 50% pain reduction is approximately 10. Duloxetine is particularly valuable for patients with central sensitisation, comorbid depression/anxiety, or NSAID contraindications. It is not approved by all regulatory agencies for OA specifically, but is widely used off-label or within licensed chronic pain indications.

6. Intra-Articular Corticosteroid Injection

Intra-articular corticosteroid (IACS) injection (methylprednisolone 40 mg or triamcinolone 40 mg) provides rapid pain relief, with benefit typically peaking at 2–3 weeks and lasting 4–8 weeks. Useful for acute inflammatory flares, as a bridge to physiotherapy, and pre-operatively. NICE acknowledges IACS as a useful adjunct; it does not recommend routine repeated injection due to potential cartilage effects with >3 injections per year.

7. Hyaluronic Acid and PRP Injections

Hyaluronic acid (viscosupplementation) is not recommended by NICE UK for knee OA due to insufficient clinical benefit over placebo in high-quality trials. The RESTORE trial (NEJM Evidence, 2021) — the largest high-quality RCT of knee OA injections — found that PRP was not superior to hyaluronic acid at 12 months. Both HA and PRP may have a role in selected patients outside UK NHS, but the evidence does not support routine use.

8. Surgical Treatment

Arthroscopic lavage and debridement is NOT recommended for OA by NICE or OARSI — large RCTs (Moseley et al., NEJM 2002; Kirkley et al., NEJM 2008) demonstrated no benefit over sham surgery. Unicompartmental knee arthroplasty (UKA) for isolated medial or lateral compartment disease offers faster recovery than TKA with equivalent 10-year outcomes in appropriately selected patients. Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are among the most successful elective operations performed, with 15-year implant survival exceeding 90% in registry data. Patient satisfaction post-THA (~90%) is consistently higher than post-TKA (~80%), partly due to differing patient expectations and residual anterior knee pain.

9. Emerging Therapies

Lorecivivint (a CLK2/DYRK1A inhibitor targeting the Wnt pathway) progressed to Phase III trials but did not demonstrate significant benefit in the primary endpoint. Sprifermin (recombinant human FGF18) showed cartilage thickness preservation in Phase II trials (FORWARD trial, NEJM 2019), suggesting disease-modifying potential — Phase III results are awaited. Biologics (anti-IL-1, anti-IL-6, anti-NGF) remain investigational for OA; anti-NGF antibodies (tanezumab) were withdrawn due to paradoxical rapid joint destruction in a subset of patients.

A structured, guideline-aligned approach to osteoarthritis management delivers measurable benefits across multiple domains:

• Pain reduction: Supervised exercise programmes reduce pain by 20–30% (comparable to oral NSAIDs without side effects); structured weight loss of >10% provides additional analgesic benefit. Multimodal pharmacological management can achieve 40–60% pain reduction in moderate OA.
• Improved function and mobility: Exercise improves walking speed, stair climbing, and sit-to-stand performance, directly correlating with reduced falls risk in older adults — a critical benefit in the osteoarthritis age group.
• Delay of surgical intervention: Optimised non-surgical management consistently delays the need for joint replacement by several years in prospective cohort studies. The GLA:D programme reduced the proportion of patients proceeding to TKA within 6 years by approximately 40% in Danish registry data.
• Reduced analgesic dependence: Effective exercise and weight management reduce the requirement for NSAIDs, opioids, and injections, thereby reducing exposure to pharmacological side effects — particularly important in elderly patients with multiple comorbidities.
• Improved mental health: OA is strongly associated with depression and anxiety; exercise has well-established antidepressant effects and improves self-efficacy, sleep, and social engagement alongside its direct analgesic properties.
• Excellent surgical outcomes when needed: When non-surgical management is exhausted, TKA and THA consistently achieve high patient satisfaction and implant longevity >90% at 15 years in national joint registry data. THA is consistently among the most cost-effective interventions in all of medicine on quality-adjusted life year (QALY) metrics.

Each component of OA treatment carries specific risks that require patient counselling and clinical monitoring:

Exercise: Appropriately graduated exercise is very safe for OA. Initial increase in joint discomfort for 24–48 hours after new exercise (DOMS) is normal. Rare risk of joint injury with inappropriate high-impact exercise; physiotherapist-supervised programmes are recommended initially.

Topical NSAIDs: Local skin irritation (erythema, dry skin) in up to 10% of users. Avoid on broken or infected skin. Minimal systemic absorption means GI, cardiovascular, and renal risks are negligible.

Oral NSAIDs: GI: peptic ulceration, dyspepsia, upper GI bleed (risk 1–2% per year without PPI; PPI co-prescription reduces risk by 80%). Cardiovascular: fluid retention, blood pressure elevation, increased MI and stroke risk — particularly with diclofenac and COX-2 inhibitors. Renal: worsening CKD; avoid or use minimum dose in eGFR <30 mL/min. Drug interactions: potentiate anticoagulants and increase lithium levels.

Duloxetine: Common side effects: nausea (50% initially, resolves after 2 weeks in most), dry mouth, constipation, insomnia, and sexual dysfunction. Serotonin syndrome risk with concurrent serotonergic agents. Discontinuation syndrome with abrupt cessation — always taper over minimum 2 weeks. Monitor liver function in hepatic impairment.

Intra-articular corticosteroid: Transient pain flare 12–24 hours post-injection (steroid flare) occurs in 5–10% — reassure patient and manage with ice and simple analgesia. Systemic glycaemic effect in diabetics (monitor blood glucose 24–48 hours post-injection). Theoretical accelerated cartilage loss with >3 injections/year in the same joint — a pragmatic maximum of 3 per year per joint is widely applied.

Joint replacement surgery: TKA risks: surgical site infection (0.5–1%), DVT/PE (thromboprophylaxis mandatory), aseptic loosening at 10–15 years (may require revision), periprosthetic fracture, stiffness (manipulation under anaesthesia may be required). Persistent pain post-TKA affects ~20% of patients and is multifactorial. THA risks: dislocation (0.5–3%), leg length discrepancy, acetabular or femoral component failure, neurovascular injury.

Osteoarthritis is a chronic progressive disease requiring ongoing management review rather than one-time treatment. The following framework supports long-term follow-up:

Non-surgical management review (every 3–6 months initially): Pain VAS or NRS (0–10), functional questionnaires (KOOS — Knee Injury and Osteoarthritis Outcome Score; HOOS for hip; FIHOA for hand OA), and weight/BMI monitoring should be recorded at baseline and at each review. OARSI recommends periodic reassessment of the management plan to escalate or de-escalate treatment based on response.

Exercise programme review: At 8–12 weeks, assess adherence, pain response, and functional improvement. Refer to a physiotherapist or structured OA exercise programme (GLA:D, ESCAPE-pain) if self-directed exercise has been insufficient. Long-term exercise adherence is the key determinant of outcome — patient-specific motivational strategies (behaviour change techniques, BCTs) improve sustained exercise participation.

NSAID monitoring: Renal function (eGFR), electrolytes, and blood pressure at 3 months for patients on regular oral NSAIDs, then annually. Review continuing need at every consultation — use the lowest effective dose for the shortest duration. Reassess cardiovascular risk annually.

Duloxetine monitoring: Hepatic function at baseline and 3 months. Efficacy assessment at 8–12 weeks. Suicidality monitoring during initiation per standard antidepressant monitoring protocols.

Surgical follow-up: Post-TKA and THA: wound review at 2 weeks, physiotherapy and walking assessment at 6 weeks, radiographic review at 3 months, then annually at specialist clinic or via national joint registry protocol. The National Joint Registry (NJR, UK) and Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) provide long-term implant surveillance. Revision surgery should be considered when chronic pain, instability, infection, or implant failure is confirmed.

Disease progression monitoring: X-rays are not required routinely in OA management but are performed when symptoms change significantly, when surgery is being considered, or to confirm prosthesis position and integration post-operatively.

Osteoarthritis imposes a substantial economic burden on individuals and healthcare systems globally. Cost considerations span from low-cost lifestyle modifications to major surgery:

Non-pharmacological treatment: Exercise programmes are relatively low cost. GLA:D group physiotherapy: approximately USD 200–500 for an 8-week course. Aquatic physiotherapy: USD 40–100 per session. Commercial weight management programmes: USD 100–500. Knee unloading braces: USD 200–700 off-the-shelf.

Pharmacological treatment: Topical diclofenac gel: USD 10–40/month (generic). Generic oral NSAIDs (naproxen, ibuprofen): USD 5–20/month. Duloxetine generic: USD 15–60/month in most markets. Etoricoxib: USD 30–100/month depending on country.

Intra-articular injections: Corticosteroid injection: USD 100–500 (with ultrasound guidance); covered by most insurance when medically indicated. PRP injection: USD 500–2,500 per injection; typically self-funded as not covered by insurance given inconclusive evidence. HA injection: USD 200–1,500 per course; coverage varies by country and insurer.

Joint replacement surgery: TKA costs: USD 12,000–35,000 (USA, private); GBP 8,000–15,000 (UK, private); USD 4,000–10,000 (India, Thailand). THA costs: similar range. These figures typically include surgeon, anaesthesia, hospital stay (2–4 nights), prosthesis, and immediate rehabilitation. Post-operative physiotherapy (6–12 weeks) adds USD 1,000–3,000.

Medical tourism for joint replacement: India (Apollo, Fortis, Manipal), Thailand (Bumrungrad, Vejthani), and Mexico are leading destinations for TKA and THA at significantly reduced cost (30–70% savings vs USA/Australia/UK). Quality at accredited JCI centres is comparable to Western standards, but patients must factor in flights, accommodation, post-operative complications management abroad, and limited recourse if revision surgery is needed.

Beyond the established treatment pathway, several alternative and emerging options deserve consideration in specific patient contexts:

Partial knee resurfacing (unicompartmental knee arthroplasty, UKA): For patients with isolated medial or lateral knee compartment OA and intact ACL, UKA preserves the native bone and ACL compared with TKA, allows faster recovery (discharge day 1–2 vs day 2–4 for TKA), and achieves equivalent pain relief in appropriately selected patients. Revision rates are slightly higher at 10 years than TKA (~10% vs 5%), but revision back to TKA is straightforward. Robotic-assisted UKA (Mako robot) demonstrates improved component alignment in early data.

High tibial osteotomy (HTO): A bone-realignment procedure that shifts weight-bearing away from the diseased medial compartment of the knee by correcting varus deformity. Suitable for younger, active patients (<60 years) with isolated medial compartment OA and significant varus malalignment who wish to delay TKA. Buys time — typically 10–15 years — before TKA is required.

Cartilage restoration procedures: Microfracture, osteochondral autograft transfer (OATS/mosaicplasty), and autologous chondrocyte implantation (ACI/MACI) are used for focal full-thickness cartilage defects in young patients, but are generally not appropriate for established diffuse OA.

Radiofrequency ablation of genicular nerves: Percutaneous radiofrequency ablation of the genicular nerves (superior medial, superior lateral, inferior medial) provides pain relief lasting 6–12 months in patients with severe knee OA unsuitable or unwilling to undergo surgery. A minimally invasive option with emerging evidence and an acceptable safety profile.

GLP-1 receptor agonists (semaglutide): Weight loss agents such as semaglutide (Ozempic/Wegovy) achieve 15–20% body weight reduction in obese patients, profoundly reducing knee OA symptoms. The SUSTAIN-OA and SELECT trial data demonstrate clinically meaningful pain and function improvements potentially attributed to both weight loss and direct anti-inflammatory effects. A growing body of evidence supports their role in OA management in obese patients.

Acupuncture: NICE (NG193) recommends acupuncture for chronic primary pain. Meta-analyses show small but significant benefits for knee and hip OA pain beyond sham acupuncture, though the clinical significance remains debated. May be appropriate as an adjunct for patients declining pharmacological treatment.